Agonistas do receptor de GLP-1 no emagrecimento estético
revisão narrativa sobre riscos à saúde e efeitos adversos
DOI:
https://doi.org/10.61695/rcs.v4i1.94Palavras-chave:
estética corporal, agonistas do receptor de GLP-1, Semaglutida, Tirzepatida, obesidadeResumo
The use of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, has expanded beyond approved clinical indications and is increasingly reported in aesthetic weight loss practices. This narrative review aimed to analyze the scientific literature regarding efficacy, adverse effects, and ethical implications of the off-label use of these medications in healthy individuals. Twelve articles published over the past ten years were selected using the Connected Papers platform, addressing mechanisms of action, clinical outcomes, and safety profiles. The findings indicate high efficacy in weight reduction and cardiometabolic improvement among individuals with established therapeutic indications; however, no evidence was identified regarding efficacy or safety in normoweight populations. Gastrointestinal symptoms were the most frequently reported adverse effects and were generally mild and transient; serious events were rare, although potential risks may be underestimated in healthy individuals. Ethical and social concerns related to the medicalization of aesthetic weight loss were also identified, including self-medication, inappropriate use, and inequitable access. In conclusion, the aesthetic use of GLP-1 receptor agonists lacks scientific support and may pose avoidable health risks. Further studies are needed to evaluate safety, social determinants, and the influence of digital media, as well as to support health education strategies and ethical prescribing guidelines.
Downloads
Referências
Brasil. Ministério da Saúde. Pesquisa Nacional de Saúde 2019/2020: excesso de peso e obesidade em adultos. Brasília: Ministério da Saúde; 2020. Disponível em: https://agenciadenoticias.ibge.gov.br/agencia-noticias/2012-agencia-de- noticias/noticias/29204-um-em-cada-quatro-adultos-do-pais-estava-obeso-em- 2019. Acesso em: 04 out. 2025.
World Health Organization. World health statistics 2023: monitoring health for the SDGs, sustainable development goals. Geneva: WHO; 2023. Disponível em: https://www.who.int/data/gho/publications/world-health-statistics. Acesso em: 04 set. 2025.
International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels: International Diabetes Federation; 2025. Disponível em: https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition
_2025.pdf. Acesso em: 04 out. 2025.
Młynarska E, Bojdo K, Bulicz A, Frankenstein H, Gąsior M, Kustosik N, et al. Obesity as a multifactorial chronic disease: molecular mechanisms, systemic impact, and emerging digital interventions. Curr Issues Mol Biol. 2025;47(10):787. doi:10.3390/cimb47100787.
Mayoral LP, Andrade GM, Mayoral EP, Huerta TH, Canseco SP, Rodal Canales FJ, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020;151(1):11–21. doi:10.4103/ijmr.IJMR_1768_17.
Santos RF, Deuner MC. Riscos associados ao uso indiscriminado de semaglutida (Ozempic). Rev JRG Estud Acad. 2024;7(14):e141185. doi:10.55892/jrg.v7i14.1185.
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945.
Duarte BLC, Vieira Lins FS, et al. Effectiveness and adverse effects of semaglutide in the treatment of obesity: a literature review. Rev Multidiscip Nordeste Mineiro. 2025;9(1):1–15. doi:10.61164/rmnm.v9i1.3948.
Lingow S, Carris N, Clements J, et al. The pharmacist's role in the use of incretin-based therapies for weight management: an opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. J Am Coll Clin Pharm. 2025;8(10):1078–1093. doi:10.1002/jac5.70111.
Moiz A, et al. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363. doi:10.1016/j.eclinm.2025.103363.
Trabulsi RK, Oliveira AFSM, Bezerra CMF, Lima JB, Sousa CES, Pacheco IA, et al. As consequências clínicas do uso de Ozempic para tratamento da obesidade: uma revisão de literatura. Braz J Health Rev. 2023;6(3):12297– 12312. doi:10.34119/bjhrv6n3-305.
Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X.
Wilding JPH, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183.
Timo AMT, Meneghetti AJP, Barbosa GP, Barros MM, Souza VR, Andrade IF, et al. Uso de semaglutina no tratamento da obesidade. Braz J Health Rev. 2022;5(3):10430–10440. doi:10.34119/bjhrv5n3-207.
Zanatta MCA, Rocha FS, Fumagali TAS, Backes GA, Sambini TB, Matsukuma IS, Martinez GA, Benedetti ATS, Pereira LA. Semaglutide applied to the treatment of obesity: clinical perspectives in the literature. Res Soc Dev. 2023;12(9):e10012943295. doi:10.33448/rsd-v12i9.43295.
Kamrul-Hasan ABM, Alam MS, Dutta D, Sasikanth T, Aalpona FTZ, Nagendra
L. Tirzepatide and cancer risk in individuals with and without diabetes: a systematic review and meta-analysis. Endocrinol Metab (Seoul). 2025;40(1):112–124. doi:10.3803/EnM.2024.2164.
Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Joy B, Kou M, Muttalib Z, Alam A, Frezza E. Evaluating the rates of pancreatitis and pancreatic cancer among GLP-1 receptor agonists: a systematic review and meta-analysis of randomised controlled trials. Endocrinol Diabetes Metab. 2025;8(5):e70113. doi:10.1002/edm2.70113.
Staico BM, et al. O uso de análogos de GLP-1 liraglutida, semaglutida e tirzepatida no tratamento da obesidade: uma revisão de literatura. RECIMA21. 2023;4(4):e442950. doi: 10.47820/recima21.v4i4.2950.
Silva AB, Simões DVS, Ishiuchi GGC. Impactos gerais e riscos do uso da semaglutida para fins estéticos. Observatorio de la Economia Latinoamericana. 2024;22(11):1–14. doi:10.55905/oelv22n11-224.
Silva AVF, Santos LB, Queiroz FJG. Os riscos do uso de medicações para o emagrecimento = The risks of using weight loss medications. JRG Estudos Acad. 2022;5(V):11–56. doi: 10.5281/zenodo.7110774.
Sousa DTC, Meneses FG, Silva GLM, Cipriano VTF. Risco do uso indiscriminado de medicamentos para emagrecimento / Risk of indiscriminate use of medicines for slimming. Braz J Health Rev. 2021;4(6):28589–28602. doi: 10.34119/bjhrv4n6-402.
Meng Z, Yang M, Wen H, Zhou S, Xiong C, Wang Y. A systematic review of the safety of tirzepatide—a new dual GLP1 and GIP agonist—is its safety profile acceptable? Front Endocrinol (Lausanne). 2023;14:1121387. doi: 10.3389/fendo.2023.1121387.
Forst T, De Block C, Del Prato S, Armani S, Frias J, Lautenbach A, Ludvik B, Marinez M, Mathieu C, Müller TD, Schnell O. The role of incretin receptor agonists in the treatment of obesity. Diabetes Obes Metab. 2024;26(10):4178–4196. doi: 10.1111/dom.15796.
Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024;75:102782. doi: 10.1016/j.eclinm.2024.102782.
Srivastava G, Campbell SL, Hill CR, Stanley TL, Lawson EA, Apovian CM, Almandoz JP, Leggio L, Lakdawalla DN, Dar M, Socolovsky C, Stanford FC, Armstrong S, Grinspoon SK. Novel strategies for medical management of obesity: mechanisms, clinical implications, and societal impacts—a report from the 25th Annual Harvard Nutrition Obesity Symposium. Am J Clin Nutr. 2025;122(3):866–885. doi:10.1016/j.ajcnut.2025.06.015.
Patel S, Niazi SK. Emerging frontiers in GLP-1 therapeutics: a comprehensive evidence base. Pharmaceutics. 2025;17(8):1036. doi: 10.3390/pharmaceutics17081036.
O'Keefe JH, Franco WG, O'Keefe EL. Anti-consumption agents: tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy. Prog Cardiovasc Dis. 2025;89:102–112. doi:10.1016/j.pcad.2024.12.010.
Schmitz SH, Aronne LJ. Using second-generation anti-obesity medications. Diabetes Spectr. 2024;37(4):303–312. doi: 10.2337/dsi24-0002.
Jensen EL, Israelsen M, Krag A. Transforming steatotic liver disease management: the emerging role of GLP-1 receptor agonists. Hepatology Commun. 2024;8(11):e0561. doi: 10.1097/HC9.0000000000000561.
Salvador J. GLP-1-based medications: mechanisms involved in obesity treatment. Med Clin (Barc). 2025;165(1):107035. doi: 10.1016/j.medcli.2025.107035.
Bailey CJ, Flatt PR, Conlon JM. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025;187:171380. doi: 10.1016/j.peptides.2025.171380.
MacIsaac RJ. Semaglutide: a key medication for managing cardiovascular- kidney-metabolic syndrome. Future Cardiol. 2025 Jul;21(9):663-683. doi: 10.1080/14796678.2025.2511412. Epub 2025 Jun 3. PMID: 40458885; PMCID: PMC12258229.
Behera PK, Jain SJ, Kumar A. Exploração visual da literatura usando artigos conectados: uma abordagem prática. Issues Sci Technol Librariansh. 2023;(104). doi: 10.29173/istl2760.
Maio EADC, Ramos FAB, Barbosa FCA, Sousa FL, Souza EAA, Oliveira LGC, Noronha MVF. A urgência para emagrecer, corpo versus saúde: análise de conteúdo das redes sociais. Revista Diálogos: Economia e Sociedade. 2021;5(1). Disponível em: https://periodicos.saolucas.edu.br/dialogos/article/view/1060. Acesso em: 08 out. 2024.
Baroni MED, Maffra MM, Oliveira AAR, Polakiewicz RR. O crescente uso de análogos do GLP-1 para perda de peso: uma ameaça à saúde ou uma solução viável para o controle de peso? J Arch Health. 2025;6(3):e2521. doi: 10.46919/archv6n3-009.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Ana Beatriz Caetano Peixoto de Camargo, Damares de Campos Cândido, Katharine Bianchini Matos, Maria Eduarda Carricondo Leite de Almeida Pereira, Maria Eduarda Romero Siqueira Campos, Patrícia Palma Navarrete, Thais Ranielle Souza de Oliveira
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
